Abstract
Dipeptidyl peptidases 4 (DPP4) inhibitors are a new class of oral anti-hyperglycemic drugs for the treatment of type 2 diabetes (T2DM). They are also called “incretins” because they act by inhibiting the degradation of endogenous incretin hormones, in particular GLP-1, that mediates their main metabolic effects. DPP4 is an ubiquitous protease that regulates not only glucose and lipid metabolism, but also exhibits several systemic effects at different site levels. DPP4 inhibition improves endothelial function, reduces the pro-oxidative and the pro-inflammatory state, and exerts renal effects. These actions are mediated by different DPP4 ligands, such as cytokines, growth factors, neuotransmitters etc. Clinical and experimental studies have demonstrated that DPP4 inhibitors are efficient in protecting cardiac, renal and vascular systems, through antiatherosclerotic and vasculoprotective mechanisms. For these reasons DDP4 inhibitors are thought to be “cardiovascular protective” as well as anti-diabetic drugs. Clinical trials aimed to demonstrate the efficacy of DPP4 inhibitors in reducing cardiovascular events, independent of their anti-hyperglycemic action, are ongoing. These trials will also give necessary information on their safety.
Keywords: Dipeptidyl peptidases, diabetes mellitus, cardiovascular system, incretins.
Current Pharmaceutical Design
Title:Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection
Volume: 20 Issue: 14
Author(s): Angelo Avogaro, Saula de Kreutzenberg and Gianpaolo Fadini
Affiliation:
Keywords: Dipeptidyl peptidases, diabetes mellitus, cardiovascular system, incretins.
Abstract: Dipeptidyl peptidases 4 (DPP4) inhibitors are a new class of oral anti-hyperglycemic drugs for the treatment of type 2 diabetes (T2DM). They are also called “incretins” because they act by inhibiting the degradation of endogenous incretin hormones, in particular GLP-1, that mediates their main metabolic effects. DPP4 is an ubiquitous protease that regulates not only glucose and lipid metabolism, but also exhibits several systemic effects at different site levels. DPP4 inhibition improves endothelial function, reduces the pro-oxidative and the pro-inflammatory state, and exerts renal effects. These actions are mediated by different DPP4 ligands, such as cytokines, growth factors, neuotransmitters etc. Clinical and experimental studies have demonstrated that DPP4 inhibitors are efficient in protecting cardiac, renal and vascular systems, through antiatherosclerotic and vasculoprotective mechanisms. For these reasons DDP4 inhibitors are thought to be “cardiovascular protective” as well as anti-diabetic drugs. Clinical trials aimed to demonstrate the efficacy of DPP4 inhibitors in reducing cardiovascular events, independent of their anti-hyperglycemic action, are ongoing. These trials will also give necessary information on their safety.
Export Options
About this article
Cite this article as:
Avogaro Angelo, Kreutzenberg de Saula and Fadini Gianpaolo, Dipeptidyl-peptidase 4 Inhibition: Linking Metabolic Control to Cardiovascular Protection, Current Pharmaceutical Design 2014; 20 (14) . https://dx.doi.org/10.2174/13816128113199990474
DOI https://dx.doi.org/10.2174/13816128113199990474 |
Print ISSN 1381-6128 |
Publisher Name Bentham Science Publisher |
Online ISSN 1873-4286 |
- Author Guidelines
- Graphical Abstracts
- Fabricating and Stating False Information
- Research Misconduct
- Post Publication Discussions and Corrections
- Publishing Ethics and Rectitude
- Increase Visibility of Your Article
- Archiving Policies
- Peer Review Workflow
- Order Your Article Before Print
- Promote Your Article
- Manuscript Transfer Facility
- Editorial Policies
- Allegations from Whistleblowers
- Announcements
Related Articles
-
Modeling Loss of Microvascular Wall Homeostasis during Glycocalyx Deterioration and Hypertension that Impacts Plasma Filtration and Solute Exchange
Current Neurovascular Research OPA1 in Cardiovascular Health and Disease
Current Drug Targets Endothelial Dysfunction in Morbid Obesity
Current Pharmaceutical Design Reduction of Oxidative/Nitrosative Stress in Brain and its Involvement in the Neuroprotective Effect of n-3 PUFA in Alzheimer’s Disease
Current Alzheimer Research Fibrinogen: A Predictor of Vascular Disease
Current Pharmaceutical Design Leptin Induces Neuroprotection Neurogenesis and Angiogenesis after Stroke
Current Neurovascular Research Clinical Experience with the Use of Angiotensin Receptor Blockers in Patients with Cardiovascular, Cerebrovascular and Renal Diseases
Current Clinical Pharmacology Cardiac Aging and Insulin Resistance: Could Insulin/Insulin-Like Growth Factor (IGF) Signaling be used as a Therapeutic Target?
Current Pharmaceutical Design The Mast Cell: A Potential Therapeutic Target in Myocardial Infarction
Drug Design Reviews - Online (Discontinued) MTHFR Gene Polymorphism and Diabetic Retinopathy
Current Diabetes Reviews Oxidative Stress in the Early Stage of Psychosis
Current Topics in Medicinal Chemistry Endoplasmic Reticulum Stress Inhibition Enhances Liver Tolerance to Ischemia/Reperfusion
Current Medicinal Chemistry [11C]Meta-Hydroxyephedrine PET/CT
Current Radiopharmaceuticals Nanomaterial Based Approaches for the Diagnosis and Therapy of Cardiovascular Diseases
Current Pharmaceutical Design Conceptual Issues in Psychiatric Neuroimaging: An Update
Current Topics in Medicinal Chemistry MicroRNAs in the Diagnosis and Treatment of Unstable Angina
Current Topics in Medicinal Chemistry Drug Therapy Aimed at Adenylyl Cyclase to Regulate Cyclic Nucleotide Signaling
Endocrine, Metabolic & Immune Disorders - Drug Targets Anesthetic Cardioprotection in Clinical Practice From Proof-of-Concept to Clinical Applications
Current Pharmaceutical Design Insights Into Early and Rapid Effects of Statin Therapy after Coronary Interventions
Current Pharmaceutical Design Oxidative Stress in Tumor Angiogenesis - Therapeutic Targets
Current Pharmaceutical Design